Publications by authors named "Partha Rakshit"

The present work was carried out during the emergence of Delta Variant of Concern (VoC) and aimed to study the change in SARS CoV-2 viral load in Covishield vaccinated asymptomatic/mildly symptomatic health-care workers (HCWs) to find out the optimum isolation period. The SARS CoV-2 viral load was carried out in sequential samples of 55 eligible HCWs which included unvaccinated (UnV; n = 11), single-dose vaccinated (SDV, n = 20) and double-dose vaccinated [DDV, n = 24; short-interval (<6 weeks)] subjects. The mean load of envelope (E) gene on day 5 in SDV [0.

View Article and Find Full Text PDF

The present study aimed to determine diagnostic performance of dried blood spot (DBS) for the detection of Hepatitis B surface antigen (HBsAg) and Hepatitis C virus antibodies (anti-HCV) using CLIA at 3 different laboratories across India. DBS can serve as a simple and convenient alternative to plasma/serum for HBsAg detection. However for anti-HCV, site-specific validation of the assay is warranted.

View Article and Find Full Text PDF

Breakthrough infections with SARS-CoV-2 Delta variant have been reported in doubly-vaccinated recipients and as re-infections. Studies of viral spread within hospital settings have highlighted the potential for transmission between doubly-vaccinated patients and health care workers and have highlighted the benefits of high-grade respiratory protection for health care workers. However the extent to which vaccination is preventative of viral spread in health care settings is less well studied.

View Article and Find Full Text PDF

During the course of the COVID-19 pandemic, large-scale genome sequencing of SARS-CoV-2 has been useful in tracking its spread and in identifying variants of concern (VOC). Viral and host factors could contribute to variability within a host that can be captured in next-generation sequencing reads as intra-host single nucleotide variations (iSNVs). Analysing 1347 samples collected till June 2020, we recorded 16 410 iSNV sites throughout the SARS-CoV-2 genome.

View Article and Find Full Text PDF

Delhi, the national capital of India, experienced multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of >50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant, B.1.

View Article and Find Full Text PDF
Article Synopsis
  • The B.1.617.2 (Delta) variant of SARS-CoV-2 was first detected in Maharashtra, India, late 2020, and quickly outcompeted earlier variants like B.1.617.1 (Kappa) and B.1.1.7 (Alpha).
  • This variant shows significantly reduced sensitivity to neutralizing antibodies from both recovered individuals and vaccine recipients, with lower protection observed in those vaccinated with the ChAdOx1 serum compared to BNT162b2.
  • Due to its higher replication efficiency and ability to evade the immune response, B.1.617.2's dominance highlights the need for ongoing infection control measures even after vaccination.
View Article and Find Full Text PDF

As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being used to investigate its transmission and evolution. Against the backdrop of the global emergence of "variants of concern" (VOCs) during December 2020 and an upsurge in a state in the western part of India since January 2021, whole genome sequencing and analysis of spike protein mutations using sequence and structural approaches were undertaken to identify possible new variants and gauge the fitness of the current circulating strains. Phylogenetic analysis revealed that newly identified lineages B.

View Article and Find Full Text PDF
Article Synopsis
  • The SARS-CoV-2 B.1.617 variant was discovered in Maharashtra, India, in late 2020, raising concerns about its ability to evade antibodies.
  • Key mutations L452R and E484Q were studied to see if they together would increase this evasion effect.
  • The findings indicate that while these mutations do reduce the vaccine's effectiveness slightly, they do not work together to create a stronger resistance to the vaccines, behaving similarly to their effects when present individually.
View Article and Find Full Text PDF
Article Synopsis
  • * A novel mass spectrometric method has been developed to rapidly detect SARS-CoV-2 from naso-oropharyngeal swabs, achieving 100% specificity and 90.5% sensitivity in just 2.3 minutes.
  • * This method can detect SARS-CoV-2 peptides even in recovered patients who test negative by traditional RT-PCR, demonstrating its potential as a valuable tool for diagnosing both symptomatic and asymptomatic cases of COVID-19.
View Article and Find Full Text PDF

India first detected SARS-CoV-2, causal agent of COVID-19 in late January 2020, imported from Wuhan, China. From March 2020 onwards, the importation of cases from countries in the rest of the world followed by seeding of local transmission triggered further outbreaks in India. We used ARTIC protocol-based tiling amplicon sequencing of SARS-CoV-2 (n=104) from different states of India using a combination of MinION and MinIT sequencing from Oxford Nanopore Technology to understand how introduction and local transmission occurred.

View Article and Find Full Text PDF